Prommune, Inc. With a focus on stimulating cellular and humoral immune responses, Prommune aims to prevent and treat a wide range of viral, bacterial, and parasitic infections and diseases, including antibiotic-resistant infections. At the heart of Prommune's platform technology is a pipeline of immunoactivator peptides that not only stimulate immune responses but also eliminate accompanying inflammatory activity.

These peptides can be used as activators, molecular adjuvants, or conjugated to antigens, allowing for the generation of a diverse range of immune responses to various pathogens. Prommune currently has three candidate products at the clinical stage, specifically targeting influenza A infections in pigs. Additionally, the company is also working on a vaccine for a human parasitic infection, which is in the early stages of development.

Backed by over 20 peer-reviewed publications, Prommune's technology has been extensively researched and has shown promising therapeutic potential in both humans and animals. For more information, reach out to Prommune at info@prommuneinc. net or visit their offices at 9393 W.

110th St Suite 500, PMB#5040, Overland Park, KS 66210. Contact them at +1 (877) 426-9009